Grifols SA (NAS:GRFS)

Full Year 2024 Grifols SA Earnings Call Transcript

Feb 26, 2025 / 05:30 PM GMT

Release Date Price: $7.94 (+7.59%)

Transcript

Key Points

Positve

Grifols SA (GIFLF) achieved record revenues and adjusted EBITDA in 2024, with a 13.6% increase in Q4 revenues on a constant currency basis.
The company significantly improved its balance sheet by reducing its leverage ratio from 6.8 times to 4.6 times within the year.
Grifols SA (GIFLF) reported strong free cash flow generation, exceeding initial guidance with a year-end result of €267 million.
The biopharma business, particularly the immunoglobulin franchise, showed robust growth, with IVIG sales growing by 15.6% in Q4.
The company made substantial progress in its innovation pipeline, including advancements in fibrinogen and receiving a grant for Parkinson's research.

Negative

The diagnostic segment saw a decline of 2% on a constant currency basis in Q4, indicating challenges in this area.
Despite improvements, the adjusted EBITDA for the full year came in just shy of the initial guidance.
The company faced a significant impact from foreign exchange fluctuations, affecting its net debt and leverage ratios.
Gross margins were affected by changes in accounting for US fee-for-services and GPO fees, impacting revenue growth profiles.
There was a notable tax impact due to exceptions related to a tax audit in Spain and taxes paid on the Shanghai Rask consideration.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GRLS.MC - Grifols SA
Full Year 2024 Grifols SA Earnings Call
Feb 26, 2025 / 05:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone and welcome to Griu year 2024 financial results conference call. My name is Danny Segarra, and I'm the head of investor relations and sustain.

Today I'm joined by Grifel's Chief Executive Officer Na Chavia, Chief Financial Officer Rahul Irinabasan, and the President of BioPharma Roland Badeer. Today's call will last about an hour, including a Q&A session.

As a reminder, this call is being recorded. All materials used during the call are available on the investor relations website at griel.com.

Moving to slide 2, I would first like to share a disclaimer on forward-looking statements.

Forward-looking statements are subject to substantial risks and uncertainties. They are only valid on the day

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.